Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Rosacea: early-phase trial registry
3 of 24 indexed Rosacea trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #686 of 28,707 conditions by registered trial count.
24 US clinical trials · 3 currently recruiting · #686 of 28,707 conditions by registered trial count
Rosacea: 24 US clinical trials tracked, 3 recruiting.
Rosacea is the subject of 24 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 7 are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most active sponsor is Galderma R&D, running 5 of these trials.
Enrollment posture brief
Registry condition rosacea
OPEN 3 | RECR 13% | LATE 7 | EARLY 12 | RANK #686 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Acute Respiratory Infection (13% recruiting · 8 trials)
Rosacea lists 3 open slots (13% of 24 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Rosacea on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Rosacea is recruiting below its size-band peers.
3 of 24 indexed trials (12.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Rosacea research.
Galderma R&D accounts for 5 of 24 trials (20.8%). 17 distinct sponsors appear on at least one study for this condition label.
-
Typical Rosacea enrolment sits around 117 participants.
Median target enrolment is 117 among the 24 trials that report a genuine target (sentinel values excluded). 12 of those (50%) plan for fewer than 100 participants.
-
Rosacea research is mostly interventional.
23 interventional and 1 observational studies make up this index (95.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
24 total, page 1 of 1
The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
Integrative Skin Science and Research
NCT05942248
Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea
Wright State University
NCT06312813
Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea
Integrative Skin Science and Research
NCT06072066
Analysis of the Microbiome in Rosacea
Johns Hopkins University
NCT04108897
ORCA - Oracea® for Rosacea: A Community-based Assessment
Galderma R&D
NCT00892281
Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face
Padagis
NCT02800148
A Therapeutic Equivalence Study of Two Metronidazole 1%Topical Gel Treatments for Patients With Rosacea
Sun Pharmaceutical Industries
NCT01513863
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
Galderma R&D
NCT01318733
AGN-199201 for the Treatment of Erythema With Rosacea
Allergan
NCT01735201
Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel
Maruho Co.
NCT02576847
Genetic Basis of Rosacea
Stanford University
NCT02787616
Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
Galderma R&D
NCT01174030
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
Galderma R&D
NCT01355458
A Study to Evaluate the Safety, Tolerability, and Effects of Anatabloc® Crème in Rosacea
Rock Creek Pharmaceuticals
NCT01740934
A Study of DER 45-EV Gel to Treat Rosacea
Sol-Gel Technologies
NCT00940992
Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea
Galderma R&D
NCT01659853
Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea
Allergan
NCT01579084
Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks
Journey Medical Corporation
NCT05597462
Efficacy of Oral Minocycline (Solodyn) and Oral Minocycline (Solodyn) Plus Azelaic Acid (Finacea) for Acne Rosacea
Dermatology Specialists Research
NCT05014906
4 Week In-Use Study Evaluating How Well-Tolerated a Skin Care Product Is on Adults With Facial Redness
Bayer
NCT03841032
Rosacea and Ivermectin
Wake Forest University Health Sciences
NCT04275999
Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.
University of California, San Diego
NCT02806414
Topical Agent for Treatment of Red Skin
Mayo Clinic
NCT00279890
Timolol for the Treatment of Acne and Rosacea
Johns Hopkins University
NCT02774590
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 5 |
| Phase 3 | 5 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Rosacea records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Rosacea trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Rosacea page
24 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Rosacea trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Galderma R&D sponsors the most Rosacea trials on record, review their full trial history before evaluating a specific study. See Galderma R&D's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Rosacea condition card totals 24 registered trials; most-linked intervention AGN-199201 Vehicle; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.